In recent years, there has been uninterrupted research on novel nanomaterials, and a novel lipoprotein-like nanocomposite (RLA-rHDL@ANG) consisting of recombinant high-density lipoprotein (rHDL) and APOE-derived peptide (RLA) has therapeutic potential for the treatment of AD. Here, APOE is linked to Alzheimer disease.